In­cyte’s IDO1 up­date on its Keytru­da com­bo scores some pos­i­tive re­views

In­cyte’s lat­est cut on the da­ta from a Phase I/II study of its com­bi­na­tion ther­a­py adding Mer­ck’s check­point star Keytru­da to its close­ly watched IDO1 en­zyme in­hibitor epaca­do­stat for melanoma is con­tin­u­ing to im­press ob­servers. And that is all bod­ing well for a new­ly launched Phase III study.

By all means, it’s still ear­ly days on out­comes, but in this new pack­age re­leased ahead of ES­MO there was an im­prove­ment in the ob­jec­tive re­sponse da­ta, which hit an ORR of 55% (or 12 out of 22 pa­tients) among all pa­tients, in­clud­ing 5 com­plete re­spons­es (23%) and 7 par­tial re­spons­es (32%). Among treat­ment-naive pa­tients the ORR was 58% and oth­er tu­mor types be­ing stud­ied demon­strat­ed ORRs rang­ing from 27% to 60%, notes RBC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER